# Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.

Study · id `cardio:ct-nct04229264` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04229264](<https://clinicaltrials.gov/study/NCT04229264>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04229264

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT04229264. Randomized; no masking; primary purpose treatment. Start 2020-01-09 (actual); primary completion 2022-02-02 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT04229264, source copy `cardio:ctgov-nct04229264-2021-04-20`, retrieved 2026-10-31)
- Started: 2020-01-09 (actual) (ClinicalTrials.gov record NCT04229264, source copy `cardio:ctgov-nct04229264-2021-04-20`, retrieved 2026-10-31)
- Primary completion: 2022-02-02 (anticipated) (ClinicalTrials.gov record NCT04229264, source copy `cardio:ctgov-nct04229264-2021-04-20`, retrieved 2026-10-31)
- Completion: 2022-05-02 (anticipated) (ClinicalTrials.gov record NCT04229264, source copy `cardio:ctgov-nct04229264-2021-04-20`, retrieved 2026-10-31)
- Countries: Brazil (ClinicalTrials.gov record NCT04229264, source copy `cardio:ctgov-nct04229264-2021-04-20`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04229264-2021-04-20`, retrieved 2026-10-31)

## The registry's words

- Brief title: Efficacy and Safety of Apixaban in Reducing Restenosis and Limb Loss in PAD Patients.
- Acronym: AGRIPPA
- Condition: Critical Limb Ischemia
- Intervention (Drug): Apixaban
- Intervention (Drug): ASA
- Intervention (Drug): Clopidogrel 75mg
- Lead sponsor: Science Valley Research Institute
- Lead sponsor class: OTHER
- Collaborator: Wyeth is now a wholly owned subsidiary of Pfizer
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record: Apixaban (`cardio:apixaban`)

## Provenance

Content hash: 61ee3d3a7aa9d2b791ea2db857fdef0a82e8b713664281de016723d68bef8c8e
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
